Literature DB >> 16795079

Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line.

Ying Chen1, Seu-Mei Wang, Jiahn-Chun Wu, Shih-Horng Huang.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists cause cell death in several types of cancer cells. The aim of this study was to examine the effects of two PPARgamma agonists, ciglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 (15dPGJ2), on the survival of thyroid carcinoma CGTH W-2 cells. Both ciglitazone and 15dPGJ2 decreased cell viability in a time- and dose-dependent manner. Cell death was mainly due to apoptosis, with a minor contribution from necrosis. Increased levels of active caspase 3, cleaved poly (ADP-ribose) polymerase (PARP), and cytosolic cytochrome-c were noted. In addition, ciglitazone and 15dPGJ2 induced detachment of CGTH W-2 cells from the culture substratum. Both the protein levels and immunostaining signals of focal adhesion (FA) proteins, including vinculin, integrin beta1, focal adhesion kinase (FAK), and paxillin were decreased after PPARgamma agonist treatment. Meanwhile, reduced phosphorylation of FAK and paxillin was noted. Furthermore, PPARgamma agonists induced expression of protein tyrosine phosphatase-PEST (PTP-PEST), and of phosphatase and tensin homologue deleted on chromosome ten (PTEN). The upregulation of these phosphatases might contribute to the dephosphorylation of FAK and paxillin, since pre-treatment with orthovanadate prevented PPARgamma agonist-induced dephosphorylation of FAK and paxillin. Perturbation of CGTH W-2 cells with anti-integrin beta1 antibodies induced FA disruption and apoptosis in the same cells, thus the downregulation of integrin beta1 by PPARgamma agonists resulted in FA disassembly and might induce apoptosis via anoikis. Our results suggested the presence of crosstalk between apoptosis and integrin-FA signaling. Moreover, upregulation and activation of PTEN was correlated with reduced phosphorylation of Akt, and this consequence disfavored cell survival. In conclusion, PPARgamma agonists induced apoptosis of thyroid carcinoma cells via the cytochrome-c caspase 3 and PTEN-Akt pathways, and induced necrosis via the PARP pathway. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795079     DOI: 10.1002/jcb.20839

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

1.  Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy.

Authors:  Anne R Diers; Brian P Dranka; Karina C Ricart; Joo Yeun Oh; Michelle S Johnson; Fen Zhou; Manuel A Pallero; Thomas M Bodenstine; Joanne E Murphy-Ullrich; Danny R Welch; Aimee Landar
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

Review 2.  Environmental physical cues determine the lineage specification of mesenchymal stem cells.

Authors:  Chao Huang; Jingxing Dai; Xin A Zhang
Journal:  Biochim Biophys Acta       Date:  2015-02-26

Review 3.  Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease.

Authors:  John Caltagarone; Zheng Jing; Robert Bowser
Journal:  Biochim Biophys Acta       Date:  2006-11-30

4.  Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

Authors:  Laura A Marlow; Lisa A Reynolds; Alan S Cleland; Simon J Cooper; Michelle L Gumz; Shinichi Kurakata; Kosaku Fujiwara; Ying Zhang; Thomas Sebo; Clive Grant; Bryan McIver; J Trad Wadsworth; Derek C Radisky; Robert C Smallridge; John A Copland
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

Review 5.  Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors.

Authors:  Changxue Lu; Sheue-Yann Cheng
Journal:  J Mol Endocrinol       Date:  2009-09-09       Impact factor: 5.098

6.  PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.

Authors:  B Shen; E S H Chu; G Zhao; K Man; C-W Wu; J T Y Cheng; G Li; Y Nie; C M Lo; N Teoh; G C Farrell; J J Y Sung; J Yu
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

7.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

8.  PPARgamma, PTEN, and the Fight against Cancer.

Authors:  Rosemary E Teresi; Kristin A Waite
Journal:  PPAR Res       Date:  2008-12-14       Impact factor: 4.964

9.  The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.

Authors:  Kimberly A Placzkowski; Honey V Reddi; Stefan K G Grebe; Norman L Eberhardt; Bryan McIver
Journal:  PPAR Res       Date:  2008-10-29       Impact factor: 4.964

10.  Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.

Authors:  Gabriela Magenta; Ximena Borenstein; Romina Rolando; María Adela Jasnis
Journal:  BMC Cancer       Date:  2008-02-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.